Inst. Holders
6 funds
CERO
CERO THERAPEUTICS HOLDINGS, INC.
$0.0110 ▲ +0.00%
Prev close $0.0110High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on CERO right now — valuation, ownership and activity at a glance.
Inst. Value
$57.1K
Inst. Activity
1 buys / 1 sells
Social Sentiment
50° Neutral
SEC Reports
4
Price chart 30d +0.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 31, 2026 SEC Jul 13, 2026 SEC Jun 26, 2026 SEC
CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsecured debt into a new
8-K — Impact 7/10
Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics' securities from listing and registration, effective
25-NSE — Impact 7/10
CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions, providing
8-K — Impact 6/10
Mar 4, 2026 Insider
Francois Eric was granted 1,823,278 shares
Director
Sep 30, 2025 Inst.
UBS Group AG — NEAR_EXIT
6 shares ($30.00)
Sep 30, 2025 Inst.
BANK OF AMERICA CORP — ADD
3 shares ($15.00)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Nov 18, 2025 | D. Boral Capital | DOWNGRADE | Hold | 33% |
| Oct 30, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Oct 22, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Oct 13, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Sep 23, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Sep 9, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Sep 5, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Aug 4, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Jun 24, 2025 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Jun 23, 2025 | D. Boral Capital | UPGRADE | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jun 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 4 bearish, 0 mixed, 0 neutral · avg impact 6.8/10.
BEARISH8-K7/10
CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsec
Aug 31, 2026
BEARISH25-NSE7/10
Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics' securities from listing and reg
Jul 13, 2026
BEARISH8-K6/10
CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health S
Jun 26, 2026
BEARISH8-K7/10
CERO Therapeutics raised $750,000 through a convertible promissory note with a principal of $937,500
Mar 11, 2026
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own CERO (from quarterly 13F filings) and who is adding or trimming.
6 institutional holders with $57.1K total value (11,225 shares) as of 2025-Q3. Top holders: ROYAL, SUSQUEHANNA, CITIGROUP.
Top holders — 2025-Q3
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10,244 | $52.1K | 91.3% | — |
| CITIGROUP INC | 968 | $4.9K | 8.6% | — |
| UBS Group AG | 6 | $30.00 | 0.1% | NEAR_EXIT -99.8% |
| JONES FINANCIAL COMPANIES LLLP | 3 | $16.00 | 0.0% | — |
| BANK OF AMERICA CORP /DE/ | 3 | $15.00 | 0.0% | ADD +50.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 2,625 | 6 | -99.8% | $30.00 |
| BANK OF AMERICA CORP /DE/ | ADD | 2 | 3 | +50.0% | $15.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 1 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Francois Eric | Director | AWARD | 1,823,278 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CERO.
Shares short
2,485
Settlement Sep 15, 2026
Change vs prior
-93.1%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
All CERO filing & press-release reports (4)
- 8-K reportAug 31, 2026
- 25-NSE reportJul 13, 2026
- 8-K reportJun 26, 2026
- 8-K reportMar 11, 2026